Neurodegenerative disease management最新文献_第4页

Glatiramer acetate or IFN-β bridging therapy in women with relapsing multiple sclerosis planning a pregnancy. 醋酸格拉替默或IFN-β桥接疗法在计划妊娠的复发性多发性硬化症妇女中的应用

IF 2.6

Neurodegenerative disease management Pub Date : 2023-08-01 DOI: 10.2217/nmt-2022-0032

Kerstin Hellwig, Sandra Thiel, Sabrina Haben, Andrea I Ciplea, Anna Kurzeja

引用次数: 0

Computerized cognitive testing in patients with Parkinson's disease: an Indian perspective. 帕金森氏病患者的电脑认知测试:印度视角

IF 2.6

Neurodegenerative disease management Pub Date : 2023-08-01 DOI: 10.2217/nmt-2023-0002

Moulika Mandal, Kashish Srivastava

引用次数: 0

A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry. 与其他口服治疗多发性硬化症的药物相比，克拉宾片的疗效总结:来自MSBase注册表的结果。

IF 2.6

Neurodegenerative disease management Pub Date : 2023-08-01 DOI: 10.2217/nmt-2023-0005

Tim Spelman, Serkan Ozakbas, Raed Alroughani, Murat Terzi, Suzanne Hodgkinson, Guy Laureys, Tomas Kalincik, Anneke Van Der Walt, Bassem Yamout, Jeannette Lechner-Scott, Aysun Soysal, Jens Kuhle, Jose Luis Sanchez-Menoyo, Yolanda Blanco Morgado, Daniele LA Spitaleri, Vincent van Pesch, Dana Horakova, Radek Ampapa, Francesco Patti, Richard Macdonell, Abdullah Al-Asmi, Oliver Gerlach, Jiwon Oh, Ayse Altintas, Namita Tundia, Schiffon L Wong, Helmut Butzkueven

{"title":"A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.","authors":"Tim Spelman, Serkan Ozakbas, Raed Alroughani, Murat Terzi, Suzanne Hodgkinson, Guy Laureys, Tomas Kalincik, Anneke Van Der Walt, Bassem Yamout, Jeannette Lechner-Scott, Aysun Soysal, Jens Kuhle, Jose Luis Sanchez-Menoyo, Yolanda Blanco Morgado, Daniele LA Spitaleri, Vincent van Pesch, Dana Horakova, Radek Ampapa, Francesco Patti, Richard Macdonell, Abdullah Al-Asmi, Oliver Gerlach, Jiwon Oh, Ayse Altintas, Namita Tundia, Schiffon L Wong, Helmut Butzkueven","doi":"10.2217/nmt-2023-0005","DOIUrl":"https://doi.org/10.2217/nmt-2023-0005","url":null,"abstract":"What is this summary about?: Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments.What were the results?: Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS.What do the results mean?: The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9787063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting metabotropic glutamate receptors for the treatment of Parkinson's disease. 靶向代谢性谷氨酸受体治疗帕金森病。

IF 2.6

Neurodegenerative disease management Pub Date : 2023-08-01 DOI: 10.2217/nmt-2023-0016

Philippe Huot

引用次数: 1

Impact of a 7-day retreat for people with Parkinson's disease: a phenomenological study. 7天静修对帕金森病患者的影响:现象学研究。

IF 2.6

Neurodegenerative disease management Pub Date : 2023-08-01 DOI: 10.2217/nmt-2023-0015

Lori M Bordenave, Corrine Fritcher Nelson, Becky G Farley, Tara L McIsaac

引用次数: 0

A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis. 临床研究可以告诉我们evobrutinib(一种治疗多发性硬化症的潜在药物)的安全性。

IF 2.6

Neurodegenerative disease management Pub Date : 2023-08-01 DOI: 10.2217/nmt-2023-0003

Xavier Montalban, Daniel Wallace, Mark C Genovese, Davorka Tomic, Dana Parsons-Rich, Claire Le Bolay, Amy H Kao, Hans Guehring

{"title":"A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis.","authors":"Xavier Montalban, Daniel Wallace, Mark C Genovese, Davorka Tomic, Dana Parsons-Rich, Claire Le Bolay, Amy H Kao, Hans Guehring","doi":"10.2217/nmt-2023-0003","DOIUrl":"https://doi.org/10.2217/nmt-2023-0003","url":null,"abstract":"What is this summary about?: This summary explains the findings from a recent investigation that combined the results of over 1000 people from three clinical studies to understand the safety of evobrutinib. Evobrutinib is an oral medication (taken by mouth), being researched as a potential treatment for multiple sclerosis (MS). This medication was also investigated in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Over 1000 people have taken evobrutinib as part of three separate phase 2 clinical studies. These studies looked at how much of the drug should be taken, how safe the drug is, and how well it might work for treating a certain medical condition.What were the results?: Evobrutinib was well-tolerated by participants in all three studies. The number of side effects reported by participants taking the medication was very similar to those reported by participants taking the placebo (a 'dummy' treatment without a real drug). The most common side effects in clinical studies were urinary tract infections, headache, swelling of the nose and throat, diarrhoea and blood markers of potential liver damage (these returned to normal once the treatment was stopped).What do the results mean?: The safety data from all three clinical studies are encouraging and can be used to inform further research into using evobrutinib in MS. Clinical Trial Registration: NCT02975349 (multiple sclerosis), NCT03233230 (rheumatoid arthritis), NCT02975336 (systemic lupus erythematosus) (ClinicalTrials.gov).","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9790150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cross-sectoral collaboration among hospital professionals on rehabilitation for patients with neuromuscular diseases. 医院专业人员在神经肌肉疾病患者康复方面的跨部门合作。

IF 2.6

Neurodegenerative disease management Pub Date : 2023-06-01 DOI: 10.2217/nmt-2022-0024

Charlotte Handberg, Ulla Werlauff

引用次数: 0

Exploring the impact of caring for an individual with neurogenic orthostatic hypotension: a qualitative study. 探讨神经源性直立性低血压患者护理的影响:一项定性研究。

IF 2.6

Neurodegenerative disease management Pub Date : 2023-06-01 DOI: 10.2217/nmt-2022-0016

Katy Gallop, Ngan Pham, Grant Maclaine, Emma Saunders, Bonnie Black, Sarah Acaster

{"title":"Exploring the impact of caring for an individual with neurogenic orthostatic hypotension: a qualitative study.","authors":"Katy Gallop, Ngan Pham, Grant Maclaine, Emma Saunders, Bonnie Black, Sarah Acaster","doi":"10.2217/nmt-2022-0016","DOIUrl":"https://doi.org/10.2217/nmt-2022-0016","url":null,"abstract":"Aim: This study aimed to explore the impact of caring for an individual with neurogenic orthostatic hypotension (nOH). Methods: Informal caregivers of individuals with nOH and either Parkinson's disease, multiple system atrophy, pure autonomic failure or dementia with Lewy bodies completed semi-structured interviews. Data were analyzed using thematic analysis; the identified concepts were used to develop a conceptual model. Results: Twenty informal caregivers were interviewed. Analysis identified several areas of caregiver impact due to nOH including impact on their time, particularly a need to supervise the patient to prevent falls as well as a lack of freedom and negative physical, work and social impacts. Many reported negative emotional impacts, including worry, stress or fear about the patient falling, depression and frustration. The conceptual model shows the relationships between concepts. Conclusion: The results highlight the wide-ranging impact of nOH, and the specific impact of the fear of falls on informal caregivers' lives.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10041184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The amyloid-β pathway in Alzheimer's disease: a plain language summary. 阿尔茨海默病中的淀粉样蛋白-β通路：通俗易懂的摘要。

IF 2.3

Neurodegenerative disease management Pub Date : 2023-06-01 Epub Date: 2023-03-30 DOI: 10.2217/nmt-2022-0037

Harald Hampel, Yan Hu, John Hardy, Kaj Blennow, Christopher Chen, George Perry, Seung Hyun Kim, Victor L Villemagne, Paul Aisen, Michele Vendruscolo, Takeshi Iwatsubo, Colin L Masters, Min Cho, Lars Lannfelt, Jeffrey L Cummings, Andrea Vergallo

{"title":"The amyloid-β pathway in Alzheimer's disease: a plain language summary.","authors":"Harald Hampel, Yan Hu, John Hardy, Kaj Blennow, Christopher Chen, George Perry, Seung Hyun Kim, Victor L Villemagne, Paul Aisen, Michele Vendruscolo, Takeshi Iwatsubo, Colin L Masters, Min Cho, Lars Lannfelt, Jeffrey L Cummings, Andrea Vergallo","doi":"10.2217/nmt-2022-0037","DOIUrl":"10.2217/nmt-2022-0037","url":null,"abstract":"What is this summary about?: This plain language summary of an article published in Molecular Psychiatry, reviews the evidence supporting the role of the amyloid-β (Aβ) pathway and its dysregulation in Alzheimer's disease (AD), and highlights the rationale for drugs targeting the Aβ pathway in the early stages of the disease.Why is this important?: Aβ is a protein fragment (or peptide) that exists in several forms distinguished by their size, shape/structure, degree of solubility and disease relevance. The accumulation of Aβ plaques is a hallmark of AD. However, smaller, soluble aggregates of Aβ - including Aβ protofibrils - also play a role in the disease. Because Aβ-related disease mechanisms are complex, the diagnosis, treatment and management of AD should be reflective of and guided by up-to-date scientific knowledge and research findings in this area. This article describes the Aβ protein and its role in AD, summarizing the evidence showing that altered Aβ clearance from the brain may lead to the imbalance, toxic buildup and misfolding of the protein - triggering a cascade of cellular, molecular and systematic events that ultimately lead to AD.What are the key takeaways?: The physiological balance of brain Aβ levels in the context of AD is complex. Despite many unanswered questions, mounting evidence indicates that Aβ has a central role in driving AD progression. A better understanding of the Aβ pathway biology will help identify the best therapeutic targets for AD and inform treatment approaches.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e1/70/nmt-13-141.PMC10334247.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9775627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Wearable activity monitors to support physical activity interventions in neurodegenerative disease: a feasibility study. 可穿戴活动监测仪支持神经退行性疾病的身体活动干预:可行性研究

IF 2.6

Neurodegenerative disease management Pub Date : 2023-06-01 DOI: 10.2217/nmt-2022-0028

Hai-Jung Steffi Shih, Lori Quinn, Philippa Morgan-Jones, Katrina Long, Abigail R Schreier, Ciaran P Friel

引用次数: 0